PRIMEVAX IMMUNO-ONCOLOGY
PrimeVax Immuno-Oncology is developing a multi-mechanism treatment for cancer leveraging whole body systemic fever along with personalized neo-antigens. Our therapeutic design is to be the only one-time one-week cancer treatment. They combine dengue fever virus and autologous dendritic cells to induce a strong immune response along with personalized tumor targeting. We focus on cancer cells resistant to prior treatments.
PRIMEVAX IMMUNO-ONCOLOGY
Industry:
Biotechnology Health Care Oncology Pharmaceutical
Founded:
2015-01-01
Address:
Orange, California, United States
Country:
United States
Website Url:
http://www.primevax.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Technology used in webpage:
Squarespace Hosted
Similar Organizations
Cortexyme
Cortexyme is developing treatments for Alzheimer's and other degenerative disorders.
Geneos Therapeutics
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Neurana Pharmaceuticals
Neurana Pharmaceuticals is currently developing a novel treatment for acute muscle spasms.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
Taiho Oncology
Taiho Oncology is a pharmaceutical company that specializes in developing innovative cancer treatments.
Tivorsan Pharmaceuticals
Tivorsan Pharmaceuticals is a protein therapeutics company that focuses on treating neuromuscular disorders.
Trevarx Biomedical
Trevarx Biomedical is a biomedical startup that develops new radiopharmaceuticals.
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.primevax.com
- Host name: 198.185.159.144
- IP address: 198.185.159.144
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "PrimeVax Immuno-Oncology"
PrimeVax Immuno-Oncology - Crunchbase Company Profile
PrimeVax Immuno-Oncology is developing a multi-mechanism treatment for cancer leveraging whole body systemic fever along with personalized neo-antigens. Our therapeutic design is to …See details»
PrimeVax Immuno-Oncology - LinkedIn
PrimeVax Immuno-Oncology, Inc. is developing the only one-time, one-week cancer treatment. We use a combination of the dengue fever virus and autologous dendritic cells to induce a …See details»
Organization | PrimeVax Immuno-Oncology Inc.
Organization Overview. First Clinical Trial. 2019 NCT03989895. First Marketed Drug. None First NDA Approval. None Last Known Activity ... PrimeVax Immuno-Oncology Inc. Active …See details»
PrimeVax Immuno-Oncology - PitchBook
Jun 15, 2017 When was PrimeVax Immuno-Oncology founded? PrimeVax Immuno-Oncology was founded in 2015. Who is the founder of PrimeVax Immuno-Oncology? Boris Minev, Tony …See details»
PRIMEVAX IMMUNO-ONCOLOGY, INC. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for PRIMEVAX IMMUNO-ONCOLOGY, INC. of Orange, CA. Get the latest business insights from Dun & …See details»
PrimeVax Immuno-Oncology Receives IND Permission From FDA
Jan 7, 2019 PrimeVax Immuno-Oncology, Inc. is focused on the development of personalized immunotherapy by leveraging its PV-001 platform. The platform's goal is to enable a 1-time 1 …See details»
PrimeVax Immuno-Oncology to Present at Biocom Global Life …
Feb 22, 2017 PrimeVax Immuno-Oncology, Inc. is focused on development of personalized immunotherapy by leveraging its PV-001 platform. The platform enables PrimeVax to develop …See details»
Primevax Immuno-Oncology, Inc. - Drug pipelines, Patents, Clinical ...
Explore Primevax Immuno-Oncology, Inc. with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, Disease Domain:Neoplasms, Technology Platform ...See details»
Primevax Immuno-oncology - Overview, CEO, Products, Business
Primevax Immuno-oncology is a private company and Primevax Immuno-oncology is classified as a Non Government company. Primevax Immuno-oncology is a Biotechnology based company …See details»
PrimeVax Immuno-Oncology Receives IND Permission From FDA
Jan 9, 2019 SAN FRANCISCO /PRNewswire/ -- PrimeVax Immuno-Oncology, Inc. announced today that the company has successfully received their Investigational New Drug (IND) …See details»
Cancer Killing Virus Approved! - CancerQuest
The U.S. Food and Drug Administration recently gave the green light to a cancer treatment created by PrimeVax Immuno-Oncology Inc. that involves the use of a virus called the dengue …See details»
Overcoming tumor immune evasion with an unique arbovirus
Jan 16, 2015 PrimeVax is currently planning a Phase I trial in advanced melanoma, combining autologous tumor lysate-pulsed DC with DV as an adjuvant. The results from this trial may …See details»
PrimeVax Immuno-Oncology Receives IND Permission From FDA
Jan 8, 2019 Cancer Immunotherapy Biotech to Begin Treating Patients Soon. SAN FRANCISCO, CA, USA I January 7, 2019 I PrimeVax Immuno-Oncology, Inc. announced …See details»
Research programme: cancer immunotherapy - PrimeVax Immuno …
08 Aug 2022 PrimeVax Immuno-oncology plans a phase I trial for Malignant melanoma (Metastatic disease, Second-line therapy or greater) in USA (IV) in April 2023 (NCT03803397) …See details»
PrimeVax Immuno-Oncology Signs Exclusive Worldwide Dengue …
Jan 22, 2019 PrimeVax Immuno-Oncology, Inc. is focused on the development of personalized immunotherapy with its PV-001 platform. The platform's goal is to enable a 1-time 1-week …See details»
Overcoming tumor immune evasion with an unique arbovirus
Jan 16, 2015 Combining dendritic cell vaccination with the adjuvant effect of a strain of dengue virus may be a way to overcome known tumor immune evasion mechanisms. Dengue is …See details»
PV001 DV - AdisInsight - Springer
30 Nov 2022 PrimeVax Immuno-Oncology plans a phase II trial for Malignant Melanoma (PrimeVax Immuno-Oncology pipeline, November 2022) You need to be a logged in or …See details»
PrimeVax Immuno-Oncology - Company Profile - Tracxn
3 days ago PrimeVax is developing a dendritic cell-based vaccine for the treatment of cancer. Its lead program PV-001, is an immunotherapy combining a dengue virus adjuvant and …See details»
A Study to Evaluate the Safety and Efficacy of Intratumoral …
Sponsors PrimeVax Immuno-Oncology Most Recent Events 04 Jul 2023 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024. 04 Jul 2023 ... If your organization has a …See details»
Canada to donate almost 18 million surplus AstraZeneca doses to …
Jul 13, 2021 Canada is donating 17.7 million doses of the AstraZeneca coronavirus vaccine to help inoculate people in low- and middle-income countries, federal ministers announced Monday.See details»